TVTX

TRAVERE THERAPEUTICS, INC.

TVTX · CIK 1438533 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$491M
20182025
Net Income−$26M
20182025
Operating CF$38M
20182025
Free Cash Flow
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.5B$0.2B$0.0B$0.2B$0.2B$0.1B$0.0B$0.0B
Cost of Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Gross Profit————————
R&D Expense———$0.0B——$0.1B$0.1B
SG&A Expense$0.3B$0.3B$0.3B$0.2B$0.1B$0.1B$0.1B$0.1B
Operating Income$-0.1B$-0.3B$-0.1B$-0.3B$-0.2B$-0.1B$-0.0B$-0.0B
Net Income$-0.0B$-0.3B$-0.1B$-0.3B$-0.2B$-0.1B$-0.0B$-0.0B
EPS (Basic)$-0.29$-4.08$-1.18$-4.37$-3.01——$-0.18
EPS (Diluted)$-0.29$-4.08$-1.18$-4.37$-3.01——$-0.18

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.6B$0.6B$0.8B$0.7B$0.8B$0.6B$0.6B$0.7B
Current Assets$0.4B$0.4B$0.6B$0.5B$0.6B$0.4B$0.4B$0.5B
Cash & Equivalents$0.1B$0.1B$0.1B$0.1B$0.2B$0.1B$0.1B$0.1B
Total Liabilities$0.5B$0.5B$0.6B$0.6B$0.5B$0.4B$0.4B$0.4B
Current Liabilities$0.2B$0.2B$0.2B$0.1B$0.1B$0.1B$0.1B$0.1B
Stockholders' Equity$0.1B$0.1B$0.2B$0.0B$0.3B$0.2B$0.2B$0.3B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$0.0B$-0.2B$-0.3B$-0.2B$-0.0B$-0.0B$-0.1B$-0.0B
Investing Cash Flow$0.0B$0.1B$0.1B$-0.0B$-0.1B$-0.1B$0.0B$-0.2B
Capital Expenditures——$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$-0.0B$0.1B$0.2B$0.1B$0.2B$0.1B$-0.0B$0.2B
← Companies